NASDAQ:IMNN Imunon (IMNN) Stock Price, News & Analysis $0.64 -0.08 (-11.57%) Closing price 04:00 PM EasternExtended Trading$0.65 +0.01 (+1.92%) As of 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsInsider TradesNews and TrendsOwnershipSEC Filings About Imunon Stock (NASDAQ:IMNN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Imunon alerts:Sign Up Key Stats Today's Range$0.50▼$0.8250-Day Range$0.64▼$1.5852-Week Range$0.50▼$4.38Volume2.18 million shsAverage Volume111,021 shsMarket Capitalization$3.57 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingHold Company Overview Imunon, Inc. (NASDAQ: IMNN) is a clinical-stage biotechnology company focused on developing treatments for cancer and other serious diseases. The company uses proprietary nucleic acid delivery technologies to develop therapeutic candidates designed to stimulate the immune system or deliver genetic instructions directly to target cells. Imunon’s lead program is GEN-1, an investigational interleukin-12 gene-mediated immunotherapy intended to treat ovarian cancer. The company has evaluated GEN-1 in combination with chemotherapy and other treatments in clinical studies. Imunon’s technology platforms are also intended to support the development of DNA- and RNA-based medicines, including potential vaccines and immunotherapies. The company was formerly known as Celsion Corporation and adopted the Imunon name as it concentrated its business on immunotherapy and nucleic acid-based therapeutic approaches. Imunon is headquartered in Lawrenceville, New Jersey, and its activities are primarily focused on research, clinical development, and potential commercialization of its proprietary biotechnology programs.AI Generated. May Contain Errors. Read More Imunon Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreIMNN MarketRank™: 2.94490142316 of 5 starsImunon scored higher than 59% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingImunon has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialImunon has a consensus price target of $10.00, representing about 1,470.4% upside from its current price of $0.64.Amount of Analyst CoverageImunon has only been the subject of 1 research reports in the past 90 days.Read more about Imunon's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Imunon are expected to grow in the coming year, from ($2.68) to ($2.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Imunon is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Imunon is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImunon has a P/B Ratio of 0.28. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Imunon's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.96% of the float of Imunon has been sold short.Short Interest Ratio / Days to CoverImunon has a short interest ratio ("days to cover") of 1.49, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Imunon has recently increased by 245.77%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImunon does not currently pay a dividend.Dividend GrowthImunon does not have a long track record of dividend growth. News and Social Media3.2 / 5News Sentiment0.20 News SentimentImunon has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Imunon this week, compared to 3 articles on an average week.Search Interest6 people have searched for IMNN on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.MarketBeat Follows3 people have added Imunon to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Imunon insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,992.00 in company stock.Percentage Held by Insiders2.83% of the stock of Imunon is held by insiders.Percentage Held by Institutions4.47% of the stock of Imunon is held by institutions.Read more about Imunon's insider trading history. Receive IMNN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Imunon and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IMNN Stock News HeadlinesIMUNON Reports Third Quarter 2026 Financial Results and Provides Business UpdateNovember 12 at 8:00 AM | globenewswire.comImunon (IMNN) Projected to Post Earnings on ThursdayNovember 11 at 3:52 AM | americanbankingnews.comYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.November 12 at 1:00 AM | Profits Run (Ad)IMUNON Presents New Translational Data at SITC 2026 Demonstrating How IMNN-001 Activates and Sustains Anti-Tumor T-Cell Immunity in Advanced Ovarian CancerNovember 6, 2026 | globenewswire.comIMUNON to Hold Third Quarter 2026 Financial Results and Business Update Conference Call on Thursday, November 12, 2026November 2, 2026 | globenewswire.comImunon Updates Investor Presentation for Upcoming EngagementsOctober 27, 2026 | tipranks.comIMUNON To Sell ThermoDox Rights To VoxelDox For Glioblastoma MultiformeOctober 21, 2026 | rttnews.comIMUNON Announces Strategic Sale of ThermoDox®October 21, 2026 | globenewswire.comSee More Headlines IMNN Stock Analysis - Frequently Asked Questions How have IMNN shares performed this year? Imunon's stock was trading at $3.81 at the start of the year. Since then, IMNN stock has decreased by 83.3% and is now trading at $0.6368. How were Imunon's earnings last quarter? Imunon, Inc. (NASDAQ:IMNN) issued its earnings results on Thursday, November, 12th. The company reported ($0.64) EPS for the quarter, missing analysts' consensus estimates of ($0.55) by $0.09. Read the conference call transcript. When did Imunon's stock split? Shares of Imunon reverse split before market open on Friday, July 25th 2025.The 1-15 reverse split was announced on Wednesday, July 23rd 2025. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 24th 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Imunon? Shares of IMNN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Imunon own? Based on aggregate information from My MarketBeat watchlists, some other companies that Imunon investors own include NVIDIA (NVDA), SoundHound AI (SOUN), Archer Aviation (ACHR), Amprius Technologies (AMPX), Salesforce (CRM), C3.ai (AI) and Advanced Micro Devices (AMD). Company Calendar Today11/12/2026Last Earnings11/12/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (27m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 IMNN's financial health is in the Red zone, according to TradeSmith. IMNN has been in this zone for over 27 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:IMNN CIK749647 Webwww.imunon.com Phone(609) 896-9100Fax609-896-2200Employees20Year FoundedN/APrice Target and Rating Average Price Target for Imunon$10.00 High Price Target$10.00 Low Price Target$10.00 Potential Upside/Downside+1,470.4%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($3.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$14.49 million Net MarginsN/A Pretax MarginN/A Return on Equity-358.01% Return on Assets-132.91% Debt Debt-to-Equity Ratio2.86 Current Ratio1.82 Quick Ratio1.82 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.30 per share Price / Book0.28Miscellaneous Outstanding Shares5,611,000Free Float5,452,000Market Cap$3.57 million OptionableNot Optionable Beta2.10 Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:IMNN) was last updated on 11/12/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredElon wants to move AI off the planet. Amazon isn't ready.What if the next AI race isn't on Earth? Tim Bohen's Mission X presentation explores Elon Musk's idea of movin...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Imunon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Imunon With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
